» Articles » PMID: 32926779

Supramolecular Mechanism of Viral Envelope Disruption by Molecular Tweezers

Abstract

Broad-spectrum antivirals are powerful weapons against dangerous viruses where no specific therapy exists, as in the case of the ongoing SARS-CoV-2 pandemic. We discovered that a lysine- and arginine-specific supramolecular ligand (CLR01) destroys enveloped viruses, including HIV, Ebola, and Zika virus, and remodels amyloid fibrils in semen that promote viral infection. Yet, it is unknown how CLR01 exerts these two distinct therapeutic activities. Here, we delineate a novel mechanism of antiviral activity by studying the activity of tweezer variants: the "phosphate tweezer" CLR01, a "carboxylate tweezer" CLR05, and a "phosphate clip" PC. Lysine complexation inside the tweezer cavity is needed to antagonize amyloidogenesis and is only achieved by CLR01. Importantly, CLR01 and CLR05 but not PC form closed inclusion complexes with lipid head groups of viral membranes, thereby altering lipid orientation and increasing surface tension. This process disrupts viral envelopes and diminishes infectivity but leaves cellular membranes intact. Consequently, CLR01 and CLR05 display broad antiviral activity against all enveloped viruses tested, including herpesviruses, Measles virus, influenza, and SARS-CoV-2. Based on our mechanistic insights, we potentiated the antiviral, membrane-disrupting activity of CLR01 by introducing aliphatic ester arms into each phosphate group to act as lipid anchors that promote membrane targeting. The most potent ester modifications harbored unbranched C4 units, which engendered tweezers that were approximately one order of magnitude more effective than CLR01 and nontoxic. Thus, we establish the mechanistic basis of viral envelope disruption by specific tweezers and establish a new class of potential broad-spectrum antivirals with enhanced activity.

Citing Articles

Phosphatidylserine-exposing extracellular vesicles in body fluids are an innate defence against apoptotic mimicry viral pathogens.

Gross R, Ressin H, von Maltitz P, Albers D, Schneider L, Bley H Nat Microbiol. 2024; 9(4):905-921.

PMID: 38528146 PMC: 10994849. DOI: 10.1038/s41564-024-01637-6.


Medicinal Plants against Viral Infections: A Review of Metabolomics Evidence for the Antiviral Properties and Potentials in Plant Sources.

Adeosun W, Loots D Viruses. 2024; 16(2).

PMID: 38399995 PMC: 10892737. DOI: 10.3390/v16020218.


Lipid-Centric Approaches in Combating Infectious Diseases: Antibacterials, Antifungals and Antivirals with Lipid-Associated Mechanisms of Action.

Ostroumova O, Efimova S Antibiotics (Basel). 2023; 12(12).

PMID: 38136750 PMC: 10741038. DOI: 10.3390/antibiotics12121716.


Molecular Machines For The Control Of Transmembrane Transport.

Johnson T, Langton M J Am Chem Soc. 2023; 145(50):27167-27184.

PMID: 38062763 PMC: 10740008. DOI: 10.1021/jacs.3c08877.


Antiviral polysaccharide and antiviral peptide delivering nanomaterials for prevention and treatment of SARS-CoV-2 caused COVID-19 and other viral diseases.

Homaeigohar S, Liu X, Elbahri M J Control Release. 2023; 358:476-497.

PMID: 37164241 PMC: 10182878. DOI: 10.1016/j.jconrel.2023.05.010.


References
1.
Castellano L, Shorter J . The Surprising Role of Amyloid Fibrils in HIV Infection. Biology (Basel). 2014; 1(1):58-80. PMC: 4011035. DOI: 10.3390/biology1010058. View

2.
St Vincent M, Colpitts C, Ustinov A, Muqadas M, Joyce M, Barsby N . Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses. Proc Natl Acad Sci U S A. 2010; 107(40):17339-44. PMC: 2951442. DOI: 10.1073/pnas.1010026107. View

3.
Jackman J, Shi P, Cho N . Targeting the Achilles Heel of Mosquito-Borne Viruses for Antiviral Therapy. ACS Infect Dis. 2018; 5(1):4-8. DOI: 10.1021/acsinfecdis.8b00286. View

4.
Munch J, Rucker E, Standker L, Adermann K, Goffinet C, Schindler M . Semen-derived amyloid fibrils drastically enhance HIV infection. Cell. 2007; 131(6):1059-71. DOI: 10.1016/j.cell.2007.10.014. View

5.
Kim K, Yolamanova M, Zirafi O, Roan N, Staendker L, Forssmann W . Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI. Retrovirology. 2010; 7:55. PMC: 2914040. DOI: 10.1186/1742-4690-7-55. View